• SPX
  • $5,782.76
  • 1.23 %
  • $70.07
  • DJI
  • $42,221.88
  • 1.02 %
  • $427.28
  • N225
  • $38,997.37
  • 1.36 %
  • $522.69
  • FTSE
  • $8,172.39
  • -0.14 %
  • -$11.85
  • IXIC
  • $18,439.17
  • 1.43 %
  • $259.19
Aldeyra Therapeutics, Inc. (ALDX) Stock Price, News & Analysis

Aldeyra Therapeutics, Inc. (ALDX) Stock Price, News & Analysis

Currency in USD Disclaimer

$5.27

$0.09

(1.64%)

Day's range
$4.93
Day's range
$5.28
50-day range
$4.93
Day's range
$6.55
  • Country: US
  • ISIN: US01438T1060
52 wk range
$2.2
Day's range
$6.55
  • CEO: Dr. Todd C. Brady M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.84
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (ALDX)
  • Company Aldeyra Therapeutics, Inc.
  • Price $5.27
  • Changes Percentage (1.64%)
  • Change $0.09
  • Day Low $4.93
  • Day High $5.28
  • Year High $6.55

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/07/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $11.00
  • High Stock Price Target $12.00
  • Low Stock Price Target $10.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.51
  • Trailing P/E Ratio -7.57
  • Forward P/E Ratio -7.57
  • P/E Growth -7.57
  • Net Income $-37,542,510

Income Statement

Quarterly

Annual

Latest News of ALDX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.